The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis

Cancer
Richard T SilverN C P Cross

Abstract

Although recombinant interferon-α (rIFNα) effectively treats patients with early myelofibrosis, the effect of driver and high molecular risk (HMR) mutations has not been considered. In this phase 2 study, for the first time, the authors correlate response to rIFNα treatment with driver and HMR mutations. Patients were diagnosed using World Health Organization or International Working Group for Myeloproliferative Neoplasms Research and Treatment criteria. Only patients who had low or intermediate-1 Dynamic International Prognostic Scoring System scores with ≥15% hematopoietic bone marrow foci were included. History, symptom assessment, physical examination, and blood and bone marrow studies were performed. Genomic DNA was extracted from frozen cells, and next-generation targeted sequencing of 45 genes was performed. Either rIFNα-2b (0.5 million units subcutaneously 3 times weekly) or pegylated rIFNα-2a (45 μg weekly) with escalation was initiated. All patients were followed at the authors' institution, and regular bone marrow biopsies were encouraged. International Working Group for Myeloproliferative Neoplasms Research and Treatment and European LeukemiaNet treatment response criteria were used. Of 30 patients (16 women and 14 ...Continue Reading

References

May 31, 2001·British Journal of Haematology·A TefferiG W Dewald
Dec 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Naseema GangatAyalew Tefferi
Mar 11, 2011·Blood·Jean-Jacques KiladjianRonald Hoffman
Nov 15, 2011·Nucleic Acids Research·Greet De BaetsFrederic Rousseau
Jul 25, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Francisco CervantesArturo Pereira
Apr 27, 2013·Leukemia·A M VannucchiA Tefferi
Jan 25, 2014·Blood·Paola GuglielmelliUNKNOWN Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators
Jul 6, 2014·Blood·Elisa RumiUNKNOWN Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators
Aug 16, 2014·American Journal of Hematology·Ayalew Tefferi
Oct 31, 2014·Nucleic Acids Research·Simon A ForbesPeter J Campbell
Dec 17, 2014·Leukemia Research·Amy V JonesNicholas C P Cross
May 23, 2015·Expert Review of Hematology·Hans Carl Hasselbalch, Richard T Silver
Aug 15, 2015·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Marco PizziAttilio Orazi

❮ Previous
Next ❯

Citations

May 14, 2017·Blood·Prithviraj Bose, Srdan Verstovsek
Jan 25, 2019·Current Treatment Options in Oncology·Prithviraj BoseSrdan Verstovsek
Dec 7, 2018·Hematology·Michele Ciboddo, Ann Mullally
Dec 20, 2017·Current Opinion in Hematology·Natasha Szuber, Ayalew Tefferi
Nov 12, 2019·Expert Review of Hematology·Nicole M CruzRichard T Silver
Nov 9, 2018·Blood Cancer Journal·Guido FinazziTiziano Barbui
Jan 8, 2020·Experimental Hematology & Oncology·Brianna M CraverAngela G Fleischman
Oct 17, 2018·Expert Review of Hematology·Eran ZimranMarina Kremyanskaya
Jun 23, 2019·Current Hematologic Malignancy Reports·Lucia MasarovaSrdan Verstovsek
Sep 28, 2017·Current Hematologic Malignancy Reports·Charles Elliott Foucar, Brady Lee Stein
Oct 6, 2020·Expert Review of Hematology·Michal Bar-Natan, Ronald Hoffman
Dec 2, 2020·International Journal of Molecular Sciences·Elisa RumiEmanuela Sant'Antonio

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.